Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2018-06-21 |
MeiraGTx (USA - NY) |
|
|
validation of a production plant |
Rare diseases - Genetic diseases |
Validation of a production plant |
2018-06-19 |
Poietis (France) Prometheus, division of skeletal tissue engineering of KU Leuven (Belgium) |
3D bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration. |
|
research - development - R&D |
Technology - Services - Regenerative medicine |
Research agreement |
2018-06-18 |
Mylan (USA - PA) Lupin (India) |
etanercept biosimilar |
rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis |
commercialisation |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases |
Commercialisation agreement |
2018-06-11 |
RegenXBio (USA - MD) Avexis (USA - MA) |
products to treat Spinal Muscular Atrophy (SMA) using NAV rAAV9 vectors |
spinal muscular atrophy |
licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Milestone |
2018-06-08 |
Amicus Therapeutics (USA - NJ) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-06-07 |
Orchard Therapeutics (UK) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-06-07 |
Sarepta Therapeutics (USA - MA) |
chief medical officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-06-05 |
Iontas (UK) LG Chem (South Korea) |
therapeutic antibodies targeting undisclosed targets |
|
collaboration - research - development |
Cancer - Oncology |
Development agreement |
2018-06-05 |
InflaRx (Germany) |
|
|
opening of new premises |
Inflammatory diseases |
Opening of new premises |
2018-06-05 |
Ideaya Biosciences (USA - CA) |
head of operations, vice president |
|
nomination |
Cancer - Oncology |
Nomination |
2018-06-04 |
Sarepta Therapeutics (USA - MA) |
vice-president |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-06-04 |
Allogene Therapeutics (USA - CA) |
chief technical officer |
|
nomination |
Cancer - Oncology |
Nomination |
2018-05-31 |
Arix Bioscience (UK) Evotec (Germany) Fred Hutchinson Cancer Research Center (USA - WA) |
LAB591 to build new companies in cancer and infectious diseases |
cancer, infectious diseases |
collaboration |
Cancer - Oncology - Infectious diseases |
Collaboration agreement |
2018-05-30 |
Celltrion Healthcare (South Korea) Yonsei University Health System (South Korea) |
Fc-saxatilin |
ischemic stroke |
development - licensing |
Cerebrovascular diseases |
Development agreement |
2018-05-30 |
Five Prime Therapeutics (USA - CA) Roche (Switzerland) |
immunohistochemistry (IHC) companion diagnostic assays for use with bemarituzumab (FPA144), and FPA150 |
tumors overexpressing FGFR2b |
development |
Cancer - Oncology |
Development agreement |
2018-05-30 |
BioMolecular Therapeutics (BMT) (Republic of Korea) Samyang (Republic of Korea) |
asymmetric siRNA (asiRNA) |
undisclosed |
research |
undisclosed |
Research agreement |
2018-05-30 |
Allogene Therapeutics (USA - CA) |
board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
2018-05-30 |
Gemini Therapeutics (USA) |
chief business officer, chief medical officer |
|
nomination |
|
Nomination |
2018-05-29 |
BioNTech (Germany) |
|
|
nomination |
Cancer - Oncology - Infectious diseases |
Nomination |
2018-05-25 |
Imcheck Therapeutics (France) |
chairman of the board |
|
nomination |
Cancer - Oncology - Autoimmune diseases |
Nomination |